Document is current
Any future updates will be listed below
-
Authors
Knudsen, Hannah K.
Andrews-Higgins, Shaquita
Back-Haddix, Sandra
Lofwall, Michelle R.
Fanucchi, Laura
Walsh, Sharon L.
-
Funding
Funding for this research was provided by:
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406)
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406)
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406)
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406)
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406)
National Institutes of Health and the Substance Abuse and Mental Health Services Administration (UM1DA049406)
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 20 March 2025
First Online: 2 April 2025
Declarations
:
: This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. All participants provided verbal informed consent prior to being interviewed.
: Not applicable.
: HKK, SBH, SAH, and LF declare that they have no competing interests. In the last three years, ML has been a research consultant for Braeburn Pharmaceuticals, Berkshire Biomedical, and Journey Colab, and has received a speaker honorarium for an invited research talk from Camurus. SW has served as a scientific advisor to Cerevel Therapeutics, Astra Zeneca, Kinoxis, Reacx, Titan, and Braeburn Pharmaceuticals.
